Clinical characteristics affecting weight loss in an East Asian population receiving semaglutide: A STEP 6 subgroup analysis
Open Access
- 1 November 2024
- journal article
- Published by Elsevier in Obesity Research & Clinical Practice
- Vol. 18 (6) , 457-464
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk (GPP 2022)
- Novo Nordisk Pharma Co Ltd
This publication has 23 references indexed in Scilit:
- Weight loss outcomes with semaglutide based on diabetes severity using the individualized metabolic surgery scoreeClinicalMedicine, 2024
- Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trialThe Lancet Diabetes & Endocrinology, 2022
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without DiabetesJAMA, 2022
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or ObesityJAMA, 2021
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or ObesityJAMA, 2021
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trialThe Lancet, 2021
- Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing dataInternational Journal of Obesity, 2021
- Japanese Clinical Practice Guideline for Diabetes 2019Diabetology International, 2020
- Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic AnalysisClinical Pharmacokinetics, 2016
- World Medical Association Declaration of HelsinkiJAMA, 2013